ClinicalTrials.gov

History of Changes for Study: NCT02635945
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
Latest version (submitted June 28, 2020) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 December 16, 2015 None (earliest Version on record)
2 March 7, 2016 Conditions and Study Status
3 March 8, 2016 Study Status, IPDSharing and Conditions
4 September 15, 2016 Study Status
5 November 5, 2018 Study Status
6 June 28, 2020 Recruitment Status, Study Status, Contacts/Locations and Study Design
Comparison Format:

Scroll up to access the controls

Study NCT02635945
Submitted Date:  December 16, 2015 (v1)

Open or close this module Study Identification
Unique Protocol ID: IIBSP-PBF-2015-34
Brief Title: A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
Official Title: A Study to Assess the Efficacy of a 5-day, Once Daily 10- mg PBF-680 Oral Administration Course to Attenuate Allergen Bronchoprovocation-induced Late Asthmatic Responses (LAR) in Asthmatic Patients Controlled on Low-to-medium Dose Inhaled Corticosteroid Maintenance Monotherapy and Inhaled Short Acting Beta-2 Agonist as Rescue Bronchodilator
Secondary IDs: 2015-001957-34 [EudraCT Number]
Open or close this module Study Status
Record Verification: December 2015
Overall Status: Recruiting
Study Start: September 2015
Primary Completion: September 2016 [Anticipated]
Study Completion: September 2016 [Anticipated]
First Submitted: October 21, 2015
First Submitted that
Met QC Criteria:
December 16, 2015
First Posted: December 21, 2015 [Estimate]
Last Update Submitted that
Met QC Criteria:
December 16, 2015
Last Update Posted: December 21, 2015 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Palobiofarma SL
Responsible Party: Sponsor
Collaborators: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hospital de Sant Pau
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: No
Open or close this module Study Description
Brief Summary: This study is the second Phase-II trial analyzing efficacy outcomes of PBF-680 in asthmatic subjects, following the supportive data from the proof-of-concept trial on the effect of PBF-680 on airway hyperresponsiveness to adenosine monophasphate (AMP). The purpose of the present study is to provide an assessment on the efficacy of a 5-day treatment course of once daily, orally administered, 10-mg PBF-680 doses, to attenuate "Late Asthmatic Responses" (LAR) as a primary efficacy outcome. The study also aims at analyzing the effect of the PBF-680 treatment course on airway inflammation-related outcomes including airway hyperresponsiveness to AMP at 24 h after allergen bronchoprovocation, plus nitric oxide fraction in exhaled air (FeNO) and airway inflammatory cells counts in induced sputum under the effect of an additional 10-mg PBF-680 dose on the 6th treatment period day. Overall, the study aims at providing evidence on the efficacy of PBF-680 on outcomes, particularly the LAR, that are well established to screen valid drugs for asthma maintenance therapy.
Detailed Description:
Open or close this module Conditions
Conditions: Asthma
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Crossover Assignment
Number of Arms: 2
Masking: Double (Participant, Investigator)
Allocation: Randomized
Enrollment: 16 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: PBF-680 10 mg
2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
Drug: PBF-680
Placebo Comparator: Placebo
2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
Drug: Placebo
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Late Asthmatic Response (LAR) , measured as the fall of the forced expiratory volume (FEV1) between 3 and 10 hours postallergen bronchoprovocation
[ Time Frame: 3-to-10 hour post-allergen bronchoprovocation. ]

Secondary Outcome Measures:
1. Early Asthmatic Response (EAR), measured as the maximum FEV1 fall from the postdiluent value
[ Time Frame: within 1 hour post-allergen bronchoprovocation. ]

2. hyperresponsiveness to AMP in terms of provocative concentration causing a 20% fall (PC20) increment in response to AMP airway challenge
[ Time Frame: 24-hour post-allergen bronchoprovocation ]

3. Nitric oxide fraction in exhaled air (FeNO) on post-allergen bronchoprovocation day
[ Time Frame: 6th treatment period day ]

4. Total leukocytes per mL in induced sputum on post-allergen bronchoprovocation day
[ Time Frame: 6th treatment period day ]

5. Leukocyte differential counts per mL in induced sputum on post-allergen bronchoprovocation day.
[ Time Frame: 6th treatment period day ]

Leukocyte subpopulations from cytocentrifuged, stained preparations will be counted and expressed as percentage cell numbers per volume unit.
6. Adverse events
[ Time Frame: 2 Months ]

The occurrence of adverse events will be monitored through the complete study. Adverse events will be recorded with the following information: severity grade (mild, moderate, severe); suspected/unsuspected relationship to the study drug; duration (date and time of onset, defined as precisely as possible, and end date or if continuing at final exam)
7. Vital signs
[ Time Frame: 9 times during 2 months ]

Vital signs will include radial artery pulse rate (measured for 60 seconds), and systolic and diastolic blood pressure. Pulse rate and blood pressure will be assessed in the right arm after the patient has rested in the sitting position for at least 5 min. Vital sign values will be recorded as notable if: pulse rate <40 or >90 bpm; systolic blood pressure <90 or >140 mmHg; diastolic blood pressure <50 or >90 mmHg.
8. Number of Participants With Abnormal Laboratory Values
[ Time Frame: 4 times during 2 months ]

On visits V2+24h, V4+24h and V6+24h, venipuncture will be performed for blood laboratory evaluations. The analysis will be performed at the local laboratory, and will include: hemogram with complete blood counts and differential leukocyte counts; clinical biochemistry including electrolytes (sodium, potassium, chloride), glucose, creatinine, urea, aspartate transaminase (AST), alanine transaminase (ALT), gammaglutamyl transpeptidase (GGT) and bilirubin; and serum immunoglobulin E (IgE) (only on visit V2+24h).
9. Physical examination
[ Time Frame: 7 times during 2 months ]

10. Electrocardiogram (EKG)
[ Time Frame: 3 times during 2 months ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  1. Male and female adults aged ³18, who have signed the informed consent form prior to initiation of any study procedures.
  2. Subjects who have controlled asthma, diagnosed and determined as such as per the Global Initiative for Asthma (GINA) guidelines, with low-to-medium dose inhaled corticosteroid (ICS) as maintenance monotherapy and inhaled, short-acting β2-agonist bronchodilator as rescue medication, for a minimum 4-week period before screening visit V1. Controlled asthma under the stated therapy can be the current, stable condition presented at visits V0 and V1 or can be achieved through GINA guideline-based clinical practice through one or more discretionary V0b visits.
  3. Subjects must have a body mass index between 18 and 35 kg/m².
  4. Subjects must be able to perform acceptable spirometry in accordance with American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria for acceptability and repeatability.

Exclusion Criteria:

  1. Current smokers, smokers within six months prior to Visit V1, or subjects with an smoking history greater than 10 packs-years.
  2. Asthmatics classed as "intermittent asthma" managed in GINA-1 therapeutic step or asthmatics that need any maintenance controller medication beyond low-to-medium inhaled corticosteroid (ICS).
  3. Patients under any immunosuppressive medication whether asthma-related or indicated for any concomitant morbidities.
  4. Subjects with a history of life-threatening asthma attacks (i.e. requiring intensive care unit (ICU) admission, orotracheal intubation).
  5. Subjects with a history of a respiratory tract infection or an asthma exacerbation requiring the use of antibiotics and/or systemic corticosteroids within 4 weeks prior to visit V1, or who develop a respiratory tract infection or asthma exacerbation during the screening period. In the latter case, the subjects can be re-screened 4 weeks after the last dose of systemic corticosteroid (except for depot corticosteroids; see Table 5.5-1) or antibiotic.
  6. Subjects that received bronchial thermoplasty treatment.
  7. Subjects with a concomitant pulmonary or thoracic disease other than asthma that may compromise safety or interfere with efficacy outcomes as per site investigator assessment. This includes, but is not limited to, COPD (COPD) attributable to tobacco or α1- antitrypsin deficiency, cystic fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, active pulmonary tuberculosis, or any prior condition that led to pulmonary resection surgery or lung transplantation. Non-cystic fibrosis bronchiectasis without clinically significant morbidity, moderate α1-antitrypsin deficiency without evidence of emphysema or related COPD, or past pulmonary tuberculosis that received proper medical treatment, are acceptable provided that the condition is not expected to interfere with pulmonary function testing as per site investigator assessment.
  8. Subjects with any skin condition such as dermographism that may prevent correct interpretation of skin prick allergy tests.
  9. Subjects with symptoms of angina pectoris or with a history of confirmed coronary disease or cardiomyopathy.
  10. Subjects with A-V block in any degree, sinus bradycardia, tachyarrhythmia, unstable atrial fibrillation, long QT syndrome, corrected QT interval (QTc(F)) interval greater than 450 ms at screening EKG on visit V1, or any other EKG abnormality deemed clinically significant by the investigator.
  11. Subjects who have a clinically significant laboratory abnormality at screening blood analysis on visit V2+24h.
  12. Subjects with current uncontrolled arterial hypertension.
  13. Women of child-bearing potential, unless they are surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), are at least 2 years postmenopausal, practice abstinence, or agree to employ effective contraception from Visit 1 through final visit. Acceptable contraception procedures are oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, or use of a condom with spermicide by the sexual partner.
  14. Women supplying lactation.
  15. Receipt of any investigational drug or biological therapy within 3 months before randomization in this study, or within 5 half-lives of the investigational agent, whichever is longer. Subjects ever treated with omalizumab or other biological therapies for asthma are not eligible.
  16. History of any known immunodeficiency disorder.
  17. Subjects with a history of malignancy within the past five years, with the exception of localized basal cell carcinoma of the skin.
  18. History of treatment for alcohol or drug abuse within the past year.
  19. Subjects with any comorbidity that could affect the safety or efficacy as per site investigator assessment.
  20. Subjects not meeting other medication restrictions as stated in Table 5.5-1.
Open or close this module Contacts/Locations
Central Contact Person: Claudia Erika Delgado, MD
Telephone: +34935 53 76 34
Email: CDelgadoE@santpau.cat
Locations: Spain
Unitat de Pneumologia Experimental
[Recruiting]
Barcelona, Spain, 08025
Contact:Principal Investigator: David Ramos Barbón, MD, PhD
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services